Atrium Therapeutics, Inc. (RNA) insider trading.
In Q3 2026, insiders at Atrium Therapeutics, Inc. reported 8 non-derivative transactions on 8 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 8
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 8
- Last filed
- 2026-09-22
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Hoyos Rocio Martin | Officer · Chief Strategy Officer | 1 | 0 | 0 |
| Winslow Brendan R. | Officer · Chief Financial Officer | 1 | 0 | 0 |
| Gallagher Kathleen P. | Director, Officer · See Remarks | 1 | 0 | 0 |
| Kenney Stephanie | Officer · See Remarks | 1 | 0 | 0 |
| Boyce Sarah | Director | 1 | 0 | 0 |
| Flanagan W. Michael | Director | 1 | 0 | 0 |
| Hughes Steven George | Officer · Chief Medical Officer | 1 | 0 | 0 |
| Younis Husam | Officer · Chief Scientific Officer | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-18 | Hoyos Rocio Martin | F (D) | 8,320 | $8.95 | 38,340 | Form 4 |
| 2026-09-18 | Winslow Brendan R. | F (D) | 6,742 | $8.95 | 36,859 | Form 4 |
| 2026-09-18 | Gallagher Kathleen P. | F (D) | 11,632 | $8.95 | 119,729 | Form 4 |
| 2026-09-18 | Kenney Stephanie | F (D) | 2,375 | $8.95 | 33,085 | Form 4 |
| 2026-09-18 | Boyce Sarah | F (D) | 126,418 | $8.95 | 138,668 | Form 4 |
| 2026-09-18 | Flanagan W. Michael | F (D) | 22,812 | $8.95 | 31,974 | Form 4 |
| 2026-09-18 | Hughes Steven George | F (D) | 21,459 | $8.95 | 51,638 | Form 4 |
| 2026-09-18 | Younis Husam | F (D) | 11,216 | $8.95 | 41,441 | Form 4 |
Transaction codes in this quarter
Get RNA insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=2093101&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · RNA company page · Atrium Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Atrium Therapeutics, Inc. (RNA)?
In Q3 2026, insiders at Atrium Therapeutics, Inc. reported 8 non-derivative transactions on 8 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Atrium Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/rna.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.